Kodiak’s stock rallies on Phase III wAMD success

Phase 3positiveZenkudaPositive

AI Analysis

Summary

Kodiak announced positive Phase III results for Zenkuda in wet age-related macular degeneration (wAMD), leading to stock rally. If approved, Zenkuda would compete with blockbuster drugs Eylea and Vabysmo in the wAMD market.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III trial success in wAMD

Importance:7/10

Sentiment:

0.75

Phase_3wAMDophthalmologypositive_datastock_rally

Related Companies

$TRAX $DMIIR $ARNA

Read the original article

Published by Clinical Trials Arena on September 28, 2026 3:09 PM

Read Original